NTLA-2001
Intellia Therapeutics
['crispr']
aha 22: results of the crispr-cas9 first-in-human trial via 
Private non-profit focused on the S.T.R.E.A.M.
Science, Technology, Robotics, Engineering, Architecture, Mathematics.